Monarch Labs and MNX Partner to Provide Expedited Shipping of Medical Maggots(TM)

October 6, 2009

IRVINE, Calif., Oct. 6 /PRNewswire/ — Monarch Labs LLC, the exclusive supplier of Medical Maggots(TM) in the United States, announced today that it has partnered with MNX to provide expedited shipping of the Medical Maggots(TM) product (disinfected Phaenicia sericata larvae) for maggot therapy. MNX provides critical and security sensitive global transportation and logistics services to diverse industries, including the life sciences industry.

Maggot therapy is the intentional introduction of live, disinfected maggots (fly larvae) into the non-healing skin and soft tissue wound(s) of a human or animal for the purposes of selectively cleaning out only the dead tissue in order to promote healing. Because Medical Maggots(TM) represent a highly perishable and living medical device, they must typically be shipped within 24 hours and used within 24 hours of receipt.

Medical Maggots(TM) received marketing clearance from the U.S. Food and Drug Administration in 2004, and since then the demand for this method of treating non-healing wounds has steadily increased.

Medical Maggots(TM) can be supplied routinely within 24 hours of request. In certain medical cases, there is a more urgent need to debride a patient’s wound with Medical Maggots(TM), and expedited shipping can best fulfill that need. MNX has a wide range of expedited and temperature-controlled delivery services, including overnight air shipping, first flight out delivery, same-day air delivery, dedicated hand carry, charter air delivery, expedited ground delivery and air delivery at schedules not served by other overnight couriers.

“We partnered with MNX to provide expedited shipping of our Medical Maggots(TM) product because of increasing customer demand for it,” Ronald Sherman, M.D., Monarch’s Laboratory Director and co-founder, said. “MNX has demonstrated the ability to rapidly and reliably deliver our Medical Maggots(TM) product to the patients who need it. Our partnership with MNX demonstrates Monarch’s strong commitment to patient care.”

About Monarch Labs

Monarch Labs is a life sciences company that researches, develops and commercializes innovative and proprietary wound care products. Monarch’s lead product is Medical Maggots(TM), the only maggots allowed for marketing in the United States as a medical device. In March 2009, Monarch launched the first wound dressing specifically designed to make maggot therapy easier and quicker to administer. The dressing has been cleared by the FDA for manufacturing and marketing under the trade name LeFlap(TM). For information, visit www.monarchlabs.com.

SOURCE Monarch Labs LLC

Source: newswire

comments powered by Disqus